ResearcherThe Ohio State University Wexner Medical CenterNo recent work listed
Heena P. Santry
Matched on ORCID iD 0000-0003-2352-1557; OpenAlex author ID A5000396481. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2020: 2 papers · 2021: 1 paper · 2022: 3 papers
Papers 6
- Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
- Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002083↗
- Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study. Co-author DOI 10.4251/wjgo.v14.i6.1175↗
- Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. Co-author DOI 10.1007/s00520-020-05813-2↗
- Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Last author DOI 10.3390/jcm9041129↗
- Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2019.7380↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jordan M. Cloyd · 6 shared papers, 2020–2022 · strength 0.83
- Paper Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000002083↗
- Paper Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative st… DOI 10.4251/wjgo.v14.i6.1175↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Timothy Michael Pawlik · 5 shared papers, 2020–2022 · strength 0.69
- Paper Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000002083↗
- Paper Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative st… DOI 10.4251/wjgo.v14.i6.1175↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Aslam M. Ejaz · 5 shared papers, 2020–2022 · strength 0.69
- Paper Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000002083↗
- Paper Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative st… DOI 10.4251/wjgo.v14.i6.1175↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Allan Tsung · 5 shared papers, 2020–2022 · strength 0.67
- Paper Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000002083↗
- Paper Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic du… DOI 10.1016/j.hpb.2021.10.010↗
- Paper Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study … DOI 10.1007/s00520-020-05813-2↗
- John F. P. Bridges · 3 shared papers, 2020–2021 · strength 0.37
- Paper Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study … DOI 10.1007/s00520-020-05813-2↗
- Paper Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.6004/jnccn.2019.7380↗
- Paper Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlle… DOI 10.3390/jcm9041129↗
- Mary E. Dillhoff · 2 shared papers, 2020 · strength 0.23
- Lena Stevens · 1 shared paper, 2022 · strength 0.16
- Ahmad B. Hamad · 1 shared paper, 2022 · strength 0.16
- Sharla Wells‐Di Gregorio · 1 shared paper, 2022 · strength 0.16
- Zachary J. Brown · 1 shared paper, 2022 · strength 0.16
- Lena Schreiber · 1 shared paper, 2022 · strength 0.15
- Eric David Miller · 1 shared paper, 2022 · strength 0.15
- Somashekar Gopala Krishna · 1 shared paper, 2022 · strength 0.15
- Anne M. Noonan · 1 shared paper, 2022 · strength 0.15
- Terence Marques Williams · 1 shared paper, 2020 · strength 0.11
- Laith I. Abushahin · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.